Fintel reports that on February 4, 2025, Piper Sandler downgraded their outlook for Amphastar Pharmaceuticals (NasdaqGS:AMPH) ...

Piper Sandler downgraded Amphastar (AMPH) to Neutral from Overweight with a price target of $36, down from $66. The firm noted that shares of ...

In a report released today, Jason Gerberry from Bank of America Securities reiterated a Hold rating on Amphastar Pharmaceuticals (AMPH – ...

A stock is considered to be oversold if the RSI reading falls below 30. In trading on Friday, shares of Amphastar Pharmaceuticals Inc (Symbol: AMPH) entered into oversold territory, hitting an RSI ...

Piper Sandler cut shares of Amphastar Pharmaceuticals (NASDAQ:AMPH – Free Report) from an overweight rating to a neutral rating in a research note issued to investors on Tuesday, Marketbeat reports.

On Tuesday, Piper Sandler adjusted its stance on Amphastar Pharmaceuticals (NASDAQ:AMPH), downgrading the company's stock rating from Overweight to Neutral and significantly reducing the price ...

On Tuesday, Piper Sandler adjusted its stance on Amphastar Pharmaceuticals (NASDAQ:AMPH), downgrading the company's stock rating from Overweight to Neutral and significantly reducing the price target ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

RANCHO CUCAMONGA, CA / ACCESSWIRE / January 8, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Jack Zhang, CEO and President, and Bill Peters, CFO will be presenting at ...

Morgan Stanley upgraded Palantir (PLTR) to Equal Weight from Underweight with a price target of $95, up from $60, following ...